Status:

COMPLETED

Precision of IMED-4 Lung Fluid Measurements

Lead Sponsor:

Intersection Medical, Inc.

Conditions:

Dyspnea

Acute Heart Failure Syndrome

Eligibility:

All Genders

18+ years

Brief Summary

The purpose of this study is to determine if IMED-4 recordings have sufficient precision to detect a clinically significant change in lung fluid status in acute heart failure syndrome with pulmonary c...

Detailed Description

The study will evaluate if the IMED-4 system has the precision to detect a clinically significant change in lung fluid status for patients with confirmed acute heart failure syndrome with pulmonary co...

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • Diagnosed with acute heart failure syndrome with pulmonary congestion defined by a Brain natriuretic peptide (BNP) \>350 pg/mL or N-terminal pro-brain natriuretic peptide (NT-pro BNP) \>1500 pg/mL and any one of the following:
  • PCWP \>25mmHg
  • Dyspnea at rest in a recumbent sitting position (30 to 45 degrees), which has worsened within the past week
  • Radiological evidence of CHF on a chest X-ray
  • Physical exam as evidence for pulmonary congestion:
  • i. Presence of an S3 heart sound ii. Lung rales/crackles/crepitations
  • Age greater than or equal to (≥) 18
  • Ability to reliably carry out self-assessment of symptoms
  • Willingness, ability and commitment to participate in index and follow-up IMED-4 recordings
  • EXCLUSION Criteria
  • Known active myocarditis, obstructive hypertrophic cardiomyopathy, constrictive pericarditis, uncorrected clinically significant primary valvular disease
  • Clinical diagnosis of acute coronary syndrome meeting any 2 of the following 3 criteria:
  • Prolonged chest pain at rest, or an accelerated pattern of angina
  • Electrocardiogram changes indicative of ischemia or myocardial injury
  • Serum troponin \>3 times upper limit of lab normal
  • Clinically-suspected acute mechanical cause of ADHF (e.g., papillary muscular rupture); the diagnosis need not be confirmed by imaging or cardiac catheterization
  • Estimated Glomerular Filtration Rate: eGFR \<30mL/min/1.73m
  • Known vasculitis, active infective endocarditis, or suspected infections including pneumonia, acute hepatitis, systemic inflammatory response syndrome, or sepsis
  • Body temperature ≥38°C just prior to enrollment
  • Acute or chronic respiratory disorder (e.g. severe chronic obstructive pulmonary disease (COPD)) or primary pulmonary hypertension sufficient to cause dyspnea at rest, which may interfere with the ability to interpret dyspnea assessments or hemodynamic measurements
  • Total Albumin \<2.5 g/dL
  • Patients requiring mechanical circulatory support
  • Pregnancy or lactation
  • Patients who have tattoos and/or non-intact skin directly under the electrode sensor position
  • Patients who have had past allergic reactions to medical grade adhesives
  • Patients who have had a lung lobectomy
  • Patients who decline to have their backs photographed with the IMED-4 device in position
  • Severe co-morbidity or poor general physical/mental health that, in the opinion of the Investigator, will not allow the subject to be a good study candidate (i.e. other disease processes, mental capacity, substance abuse, incarceration, shortened life expectance, etc.)

Exclusion

    Key Trial Info

    Start Date :

    July 1 2014

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    October 1 2015

    Estimated Enrollment :

    46 Patients enrolled

    Trial Details

    Trial ID

    NCT02187770

    Start Date

    July 1 2014

    End Date

    October 1 2015

    Last Update

    October 14 2015

    Active Locations (3)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (3 locations)

    1

    Mass General Hospital

    Boston, Massachusetts, United States, 02114

    2

    Henry Ford Hospital

    Detroit, Michigan, United States, 48202

    3

    Ohio State University

    Columbus, Ohio, United States, 43210